The Effect of Liraglutide on Renal Function: a Randomized Clinical Trial
October 17, 2016. This 12-week randomized, double-blind, placebo-controlled trial evaluated the renal effects of the glucagon-like peptide-1 agonist liraglutide in patients with type 2 diabetes (T2D) and albuminuria who were receiving multifactorial care. The primary endpoint was 24-hour geometric mean (IQR) urinary albumin excretion rate (UAER) change; 32 patients were randomized to liraglutide 1.8 mg/day or placebo. Liraglutide reduced IQR UAER by 32 units vs placebo (P=0.017), and reductions in mean glomerular filtration rate and systolic blood pressure were also observed in patients treated with liraglutide. The authors concluded that liraglutide has a renoprotective effect in the context of T2D and multifactorial treatment, including patients who use renin-angiotensin system–inhibiting drugs.